Analysts Offer Insights on Healthcare Companies: Sunesis Pharma (NASDAQ: SNSS) and Alimera (NASDAQ: ALIM)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sunesis Pharma (NASDAQ: SNSS) and Alimera (NASDAQ: ALIM).

Sunesis Pharma (NASDAQ: SNSS)

Cowen & Co. analyst Eric Schmidt reiterated a Hold rating on Sunesis Pharma (NASDAQ: SNSS) today. The company’s shares opened today at $3.69.

Schmidt observed:

“Sunesis reported Q3 financials, including $50M in pro forma cash.”

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 11.6% and a 38.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Sunesis Pharma has an analyst consensus of Moderate Buy.

Alimera (NASDAQ: ALIM)

Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Alimera (NASDAQ: ALIM) today and set a price target of $3. The company’s shares opened today at $1.14, close to its 52-week low of $1.02.

Peaker observed:

“Alimera reported 3Q16 financial results.”

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.4% and a 38.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $3.